2025-520454-11-00CompletedPhase 1
A study to investigate safety, tolerability, pharmacokinetics and efficacy of REM0045392 compared with placebo in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Nov 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 31 Jan 2025
- Start date
- 20 Mar 2025
- Lead sponsor
- Remynd
- EU CT number
- 2025-520454-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.